On the other hand, through bioinformatics, it was observed that there was a higher overall expression of PARP1 in tumors than in normal tissues and across subtypes, as well as more upregulation of mRNA in tumors than in normal tissues; such results indicate that those breast cancer patients can receive only PARP1 inhibitors. Here, PARP1 is linked to breast carcinoma.